CTNNB1 and neoplasm: Having established the molecular ground truth, we segregated tumour samples in the discovery cohort into LD (RSPO-fusions, RSPO-high and RNF43 mutations, n=64) and LI (APC or CTNNB1 mutations, n=347) subsets.